This graphic from AVAC’s Microbicides by the Numbers one-pager shows the number of ongoing microbicide trials in each phase of study.
The Number of Microbicide Trials Currently Underway
Increasing National Impact and Uptake of Good Participatory Practice Guidelines for Biomedical HIV Prevention (GPP): Three Country Case Studies
GPP provides a systematic framework for stakeholder engagement. This infographic examines how GPP was applied to the national trial oversight process in three countries: Uganda, Thailand, and South Africa. The timline plots key GPP activities and milestones from 2011-2014. This poster was presented at the 2014 HIV Research for Prevention conference in South Africa.
The Tipping Point: Moving From Rhetoric to Real Milestones for Ending AIDS
One way to measure progress in fighting AIDS is to compare the number of new HIV infections with the increase in HIV positive people on antiretroviral therapy (ART) over a given time period. An AIDS epidemic reaches its “tipping point” when the number of annual new HIV infection falls below the annual increase in patients starting ART. This poster was presented at the 2014 HIV Research for Prevention Conference in South Africa.
Tracking Investments and Expenditures in HIV Prevention Research and Development: Sustaining Funding in a Shifting International Development Landscape
This infographic shows the shifting landscape of HIV R&D. It emphasizes that funding is decreasing and that priorities are changing. This poster was presented in 2014 at the HIV Research for Prevention (R4P) conference in South Africa.
Innovation in Stakeholder Engagement: Piloting a Monitoring and Evaluation Toolkit
The M&E toolkit was developed to better understand and assess the impact of engagement on clinical trials and communities. The tools and web-based analysis database were piloted in South Africa and Kenya. This poster, presented at the 2014 HIV Research for Prevention (R4P) conference in South Africa, outlines the process and lessons learned.
Resource Tracking to Ensure Accountability and Sustainability: HIV Prevention, Treatment U=U, Diagnostics and Cure Research Investment Analysis
This infographic explains how AVAC tracks HIV expenditures and investments. This has resulted in accurate and consistent year-to-year comparisons of grants and investment figures. This poster was presented at the 2014 HIV Research for Prevention (R4P) conference in South Africa.
The Research to Rollout Timeline for Pre-Exposure Prophylaxis(PrEP)
There is a complex process for new prevention options to move from evidence of benefit in a clinical trial to being available to the public for use. This infographic traces milestones in recent years along the path from research to rollout of pre-exposure prophylaxis (PrEP). The timeline plots key dates for four major clinical trials and related guidance and regulatory decisions.
Microbicide Clinical Trials Timeline
This graphic from AVAC’s Microbicides by the Numbers one-pager tracks major ongoing and completed microbicide trials. It shows the trials that have provided the current evidence about tenofovir gel as well as planned gel and ring trials.
Microbicide Products Currently in Clinical Trials
This graphic from AVAC’s Microbicides by the Numbers one-pager shows the different products currently being studied and how advanced the research is.
Progress in VMMC Scale-up in Priority Countries
This map shows progress made through 2013 towards the target of circumcising 80% of eligible men in 14 priority countries. It is particularly useful as a tool for advocates to show how their country’s VMMC program compares to others in East and Southern Africa.